Aclarion

Leadership combines medtech commercialization and clinician‑operator DNA. Executive Chairman Dr. Jeff Thramann is a neurosurgeon‑entrepreneur; CEO Brent Ness has led commercial scaling at imaging‑heavy innovators; CFO Greg Gould adds public‑company finance depth.

Execution in 2025–2026 improved liquidity and site adds, and the team is recruiting KOLs and launching market access programs. Offsetting factors include prior dilution, reverse splits, early-stage revenue, and the complexity of payer conversion.

Governance appears active, but long‑term alignment will be proven if evidence converts into durable coverage and unit economics.